医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medacta Japan Highlights Success of 2nd Japanese M.O.R.E. Symposium

2017年11月10日 AM08:00
このエントリーをはてなブックマークに追加


 

FUKUOKA, Japan

Medacta Japan, a subsidiary of Medacta International, the privately held, family-owned global leader in the design of innovative joint replacement and spine surgery products, today announced the success of its 2nd Japanese M.O.R.E Symposium, held on September 30 to October 1, 2017 and attended by over 300 medical professionals.

Reflecting Medacta’s ongoing commitment to continuous medical education, the event focused on how implant design, techniques and patient-specific treatment can improve outcomes and patient satisfaction in the changing orthopaedic landscape, positively impacting the sustainability of the healthcare system.

More than 40 Japanese orthopaedic surgery experts presented at the meeting, covering topics on innovation, education and healthcare sustainability, with important contributions from international experts who traveled from Australia, Europe and the United States to attend the event.

“Surgical education and training has been a pillar of Medacta’s mission and identity since the company began. We believe it is the foundation for optimal clinical outcomes and both patient and surgeon satisfaction,” said Francesco Siccardi, Executive Vice President of Medacta International. “The success and the incredible growth of Medacta Japan, in both joint and spine, is a further confirmation of that belief. We’re honored that a growing number of surgeons depend on us as a reliable partner, and we will do our best to maintain our vision for a bright future in Japan.”

For more information about the 2nd Japanese M.O.R.E. Symposium and Medacta, including scientific sessions, visit: https://2more-jpn.medacta.com/.

About Medacta International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171109006703/en/

CONTACT

For Medacta International, Inc.
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者